Search

Your search keyword '"Heineken International Health Affairs"' showing total 5 results
Start Over Author "Heineken International Health Affairs" Database OpenAIRE
5 results on '"Heineken International Health Affairs"'

1. Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings

Author

Alexandra, Calmy, Eric, Balestre, Fabrice, Bonnet, Andrew, Boulle, Eduardo, Sprinz, Robin, Wood, Eric, Delaporte, Eugène, Messou, James, McIntyre, Kamal Marhoum, El Filali, Mauro, Schechter, N, Kumarasamy, David, Bangsberg, Patrick, McPhail, Stefaan, Van Der Borght, Carlos, Zala, Matthias, Egger, Rodolphe, Thiébaut, François, Dabis, HIV Unit, Geneva University Hospital, Epidémiologie et Biostatistique [Bordeaux], Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Université Bordeaux Segalen - Bordeaux 2, Service de Médecine Interne et Maladies Infectieuses, CHU Bordeaux [Bordeaux], School of Public Health and Family Medicine, University of Cape Town, South Brazil HIV Cohort, Hospital de Clínicas de Porto Alegre, Gugulethu ART Programme, Institut de Recherche pour le Développement (IRD), Centre de Prise en Charge, de Recherche et de Formation sur le VIH/SIDA, CePReF, Perinatal HIV Research Unit, Operational Research on ART (OPERA), Service des Maladies Infectieuses, Hôpital Ibn Rochd, Rio HIV Cohort, YRG Centre for AIDS Research and Education, Immune Suppression Syndrome Clinic (ISS), Helen Joseph Hospital Themba Lethu Clinic, Heineken International Health Affairs, Prospective Evaluation in the Use and Monitoring of Antiretrovirals in Argentina, PUMA, Institute of Social and Preventive Medicine (ISPM), University of Bern, The ART-LINC of IeDEA Collaboration was funded by the United States National Institute of Health (NIH - Office of AIDS Research) together with the French Agence Nationale de Recherches sur le Sida et les hépatites virales (ANRS - grants 12101 and 12138). The IeDEA network is now funded through collaborative agreements by the National Cancer Institute (NCI), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Allergy And Infectious Diseases (NIAID)., for the ART-LINC of IeDEA Collaboration (Asia, South America, East, Southern and West Africa), Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), BMC, Ed., Department of Public Health and Family Medicine, and Faculty of Health Sciences

Subjects
Male, CD4 slope, HIV Infections, 030312 virology, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Medicine, 030212 general & internal medicine, Cd4 cell count, Stage (cooking), ddc:616, 0303 health sciences, Terapia anti-retroviral de alta atividade, 3. Good health, HIV Infections/drug therapy/immunology, RNA, Viral/genetics, Infectious Diseases, HIV-RNA threshold, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, RNA, Viral, Female, low or moderate-level viremia, Research Article, Adult, Resource limited settings, medicine.medical_specialty, Anti-HIV Agents, CD4 cell counts, Viremia, CD4 count, Anti-retrovirais, lcsh:Infectious and parasitic diseases, 03 medical and health sciences, Internal medicine, Humans, lcsh:RC109-216, In patient, business.industry, medicine.disease, Antiretroviral therapy, Contagem de linfócito CD4, CD4 Lymphocyte Count, Regimen, Institutional repository, Antiretroviral treatment (ART), Anti-HIV Agents/therapeutic use, Immunology, HIV-1, business, Limited resources
Abstract

Background Changes in CD4 cell counts are poorly documented in individuals with low or moderate-level viremia while on antiretroviral treatment (ART) in resource-limited settings. We assessed the impact of on-going HIV-RNA replication on CD4 cell count slopes in patients treated with a first-line combination ART. Method Naïve patients on a first-line ART regimen with at least two measures of HIV-RNA available after ART initiation were included in the study. The relationships between mean CD4 cell count change and HIV-RNA at 6 and 12 months after ART initiation (M6 and M12) were assessed by linear mixed models adjusted for gender, age, clinical stage and year of starting ART. Results 3,338 patients were included (14 cohorts, 64% female) and the group had the following characteristics: a median follow-up time of 1.6 years, a median age of 34 years, and a median CD4 cell count at ART initiation of 107 cells/μL. All patients with suppressed HIV-RNA at M12 had a continuous increase in CD4 cell count up to 18 months after treatment initiation. By contrast, any degree of HIV-RNA replication both at M6 and M12 was associated with a flat or a decreasing CD4 cell count slope. Multivariable analysis using HIV-RNA thresholds of 10,000 and 5,000 copies confirmed the significant effect of HIV-RNA on CD4 cell counts both at M6 and M12. Conclusion In routinely monitored patients on an NNRTI-based first-line ART, on-going low-level HIV-RNA replication was associated with a poor immune outcome in patients who had detectable levels of the virus after one year of ART.

Published
2012
Full Text
View/download PDF

2. Long-term voluntary counseling and testing (VCT) uptake dynamics in a multicountry HIV workplace program in sub-Saharan Africa

Author

Stefaan van der Borght, P. Clevenbergh, Jean Pierre Kabarega, Katinka van Cranenburgh, Tobias F. Rinke de Wit, Maarten F. Schim van der Loeff, Emmanuel Kamo, Henk Rijckborst, Joep M. A. Lange, Infectious diseases, Global Health, Heineken International Health Affairs, Heineken, Cluster of Infectious Diseases, Health Services of Amsterdam, Infectious Disease Dpt, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Bralirwa S.A., Brarudi, and PharmAccess Foundation

Subjects
Adult, Counseling, Male, medicine.medical_specialty, Health (social science), Adolescent, Social Psychology, Voluntary counseling and testing, Nigeria, Occupational safety and health, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Acquired immunodeficiency syndrome (AIDS), Humans, Medicine, Africa, Central, 030212 general & internal medicine, Young adult, Workplace, Sida, Health Education, Africa South of the Sahara, 030505 public health, biology, business.industry, Public health, Public Health, Environmental and Occupational Health, Life Sciences, AIDS Serodiagnosis, HIV, virus diseases, Middle Aged, medicine.disease, biology.organism_classification, CD4 Lymphocyte Count, 3. Good health, Africa, Immunology, Lentivirus, HIV-1, Female, Health education, 0305 other medical science, business, Confidentiality, Demography
Abstract

International audience; High uptake of HIV voluntary counselling and testing (VCT) services is important for the success of HIV workplace programs in sub-Saharan Africa. From 2001 onwards Heineken, a multinational brewing company, implemented a comprehensive HIV prevention and treatment program for employees and their dependents of its African subsidiaries. Confidential in-house VCT is part of this program. VCT uptake dynamics over time, and factors associated with early uptake were studied. Between September 2001 and December 2007, 9,723 adult beneficiaries were tested for HIV in 14 company sites in 5 African countries. Three-hundred-and-seventy (3.8%) of tested persons were infected with HIV-1. During the first 12 months 1,412 tests were done, compared to 8,311 tests in the subsequent years. The annual average uptake of testing among eligible persons varied between 15% and 32%. The coverage was higher among female compared to male employees, and higher among female compared to male spouses. Distinct peaks in uptake were linked to specific local events. People aged 45 years or above, women, and HIV-1 infected persons were significantly more likely to be tested in the early period. The proportion of HIV-1 infected persons among testees was 8.8% in the first twelve months compared to 3.0% in the subsequent period (p

Published
2010
Full Text
View/download PDF

3. Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries

Author

Brinkhof, Martin, Egger, Matthias, Boulle, Andrew, May, Margaret, Hosseinipour, Mina, Sprinz, Eduardo, Braitstein, Paula, Dabis, Francois, Reiss, Peter, Bangsberg, David, Rickenbach, Martin, Miro, Jose, Myer, Landon, Mocroft, Amanda, Nash, Denis, Keiser, Olivia, Pascoe, Margaret, van Der Borght, Stefaan, Schechter, Mauro, Institute of Social and Preventive Medicine [Bern] (ISPM), Universität Bern [Bern] (UNIBE), Institute of Social and Preventive Medicine, Infectious Disease Epidemiology Unit, University of Cape Town, Department of Social Medicine, University of Bristol [Bristol], University of North Carolina [Chapel Hill] (UNC), University of North Carolina System (UNC), Infectious Diseases Unit, Universidade Federal do Rio Grande do Sul [Porto Alegre] (UFRGS), British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Epidémiologie, santé publique et développement, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR99-ISPED, CHU Bordeaux [Bordeaux], Department of Infectious Diseases, Academic Medical Centre, San Franscisco AIDS Research Institute, University of California (UC), Swiss HIV Cohort Study Data Center, Université de Lausanne = University of Lausanne (UNIL), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Department of primary care and population sciences, University College of London [London] (UCL), Mailman School of Public Health, Columbia University [New York], Newlands clinic, Heineken International Health Affairs, Serviço de Doenças Infecciosas e Parasitárias, Universidade Federal do Rio de Janeiro (UFRJ), and Mouillet, Evelyne

Subjects
MESH: Middle Aged, MESH: Humans, MESH: CD4 Lymphocyte Count, antiretroviral therapy, MESH: Adult, MESH: HIV Infections, MESH: Income, MESH: Anti-Retroviral Agents, MESH: Male, tuberculosis, low-income countries, MESH: Risk Factors, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, HIV/AIDS, industrialized countries, MESH: Tuberculosis, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Incidence, MESH: Developing Countries, MESH: Female, MESH: Developed Countries
Abstract

International audience; We examined the incidence of and risk factors for tuberculosis during the first year of highly active antiretroviral therapy in low-income (4540 patients) and high-income (22,217 patients) countries. Although incidence was much higher in low-income countries, the reduction in the incidence of tuberculosis associated with highly active antiretroviral therapy was similar: the rate ratio for months 7-12 versus months 1-3 was 0.48 (95% confidence interval, 0.36-0.64) in low-income countries and 0.36 (95% confidence interval, 0.26-0.50) in high-income countries. A low CD4 cell count at the start of therapy was the most important risk factor in both settings.

Published
2007
Full Text
View/download PDF

4. Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries

Author

Brinkhof, Martin, Egger, Matthias, Boulle, Andrew, May, Margaret, Hosseinipour, Mina, Sprinz, Eduardo, Braitstein, Paula, Dabis, Francois, Reiss, Peter, Bangsberg, David, Rickenbach, Martin, Miro, Jose, Myer, Landon, Mocroft, Amanda, Nash, Denis, Keiser, Olivia, Pascoe, Margaret, Van Der Borght, Stefaan, Schechter, Mauro, Institute of Social and Preventive Medicine [Bern] (ISPM), Universität Bern [Bern], Institute of Social and Preventive Medicine, University of Berne, Infectious Disease Epidemiology Unit, University of Cape Town, Department of Social Medicine, University of Bristol [Bristol], University of North Carolina [Chapel Hill] (UNC), University of North Carolina System (UNC), Infectious Diseases Unit, Universidade Federal do Rio Grande do Sul [Porto Alegre] (UFRGS), British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Epidémiologie, santé publique et développement, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR99-ISPED, CHU Bordeaux [Bordeaux], Department of Infectious Diseases, Academic Medical Centre, San Franscisco AIDS Research Institute, University of California, Swiss HIV Cohort Study Data Center, Université de Lausanne (UNIL), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Department of primary care and population sciences, University College of London [London] (UCL), Mailman School of Public Health, Columbia University [New York], Newlands clinic, Heineken International Health Affairs, Serviço de Doenças Infecciosas e Parasitárias, and Universidade Federal do Rio de Janeiro (UFRJ)

Subjects
MESH: Middle Aged, MESH: Humans, MESH: CD4 Lymphocyte Count, antiretroviral therapy, MESH: Adult, MESH: HIV Infections, MESH: Income, MESH: Anti-Retroviral Agents, MESH: Male, tuberculosis, low-income countries, MESH: Risk Factors, HIV/AIDS, industrialized countries, MESH: Tuberculosis, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Incidence, MESH: Developing Countries, MESH: Female, MESH: Developed Countries
Abstract

International audience; We examined the incidence of and risk factors for tuberculosis during the first year of highly active antiretroviral therapy in low-income (4540 patients) and high-income (22,217 patients) countries. Although incidence was much higher in low-income countries, the reduction in the incidence of tuberculosis associated with highly active antiretroviral therapy was similar: the rate ratio for months 7-12 versus months 1-3 was 0.48 (95% confidence interval, 0.36-0.64) in low-income countries and 0.36 (95% confidence interval, 0.26-0.50) in high-income countries. A low CD4 cell count at the start of therapy was the most important risk factor in both settings.

Published
2007
Full Text
View/download PDF

5. Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries

Author

Antiretroviral, Therapy in Low-Income Countries Collaboration of the Internation, Cohort Collaboration, ART, Brinkhof, MW, Egger, M, Boulle, A, May, M, Hosseinipour, M, Sprinz, E, Braitstein, P, Dabis, F, Reiss, P, Bangsberg, DR, Rickenbach, M, Miro, JM, Myer, L, Mocroft, A, Nash, D, Keiser, O, Pascoe, M, van der Borght, S, Schechter, M, Institute of Social and Preventive Medicine [Bern] (ISPM), Universität Bern [Bern], Institute of Social and Preventive Medicine, University of Berne, Infectious Disease Epidemiology Unit, University of Cape Town, Department of Social Medicine, University of Bristol [Bristol], University of North Carolina [Chapel Hill] (UNC), University of North Carolina System (UNC), Infectious Diseases Unit, Universidade Federal do Rio Grande do Sul [Porto Alegre] (UFRGS), British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Epidémiologie, santé publique et développement, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR99-ISPED, CHU Bordeaux [Bordeaux], Department of Infectious Diseases, Academic Medical Centre, San Franscisco AIDS Research Institute, University of California, Swiss HIV Cohort Study Data Center, Université de Lausanne (UNIL), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Department of primary care and population sciences, University College of London [London] (UCL), Mailman School of Public Health, Columbia University [New York], Newlands clinic, Heineken International Health Affairs, Serviço de Doenças Infecciosas e Parasitárias, Universidade Federal do Rio de Janeiro (UFRJ), Amsterdam institute for Infection and Immunity, Amsterdam Public Health, and Infectious diseases

Subjects
Male, Pediatrics, MESH: CD4 Lymphocyte Count, HIV Infections, Rate ratio, 0302 clinical medicine, Risk Factors, low-income countries, MESH: Risk Factors, MESH: Tuberculosis, MESH: Incidence, 030212 general & internal medicine, MESH: Developing Countries, 0303 health sciences, MESH: Middle Aged, Incidence, Incidence (epidemiology), MESH: HIV Infections, Middle Aged, 3. Good health, Infectious Diseases, Anti-Retroviral Agents, tuberculosis, Income, HIV/AIDS, Female, Developed country, Adult, Microbiology (medical), medicine.medical_specialty, Tuberculosis, antiretroviral therapy, Developing country, MESH: Anti-Retroviral Agents, Article, 03 medical and health sciences, medicine, Humans, Risk factor, Developing Countries, MESH: Developed Countries, MESH: Humans, 030306 microbiology, business.industry, Developed Countries, MESH: Adult, Risk factors for tuberculosis, MESH: Income, medicine.disease, MESH: Male, Confidence interval, CD4 Lymphocyte Count, Surgery, industrialized countries, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, MESH: Female
Abstract

International audience; We examined the incidence of and risk factors for tuberculosis during the first year of highly active antiretroviral therapy in low-income (4540 patients) and high-income (22,217 patients) countries. Although incidence was much higher in low-income countries, the reduction in the incidence of tuberculosis associated with highly active antiretroviral therapy was similar: the rate ratio for months 7-12 versus months 1-3 was 0.48 (95% confidence interval, 0.36-0.64) in low-income countries and 0.36 (95% confidence interval, 0.26-0.50) in high-income countries. A low CD4 cell count at the start of therapy was the most important risk factor in both settings.

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results